

# New therapeutic Insights Against Fungal Infections Derived from Crocodiles

Zijie Zhang<sup>1,\*</sup>

<sup>1</sup>College of Biological Science,  
University of California, Davis,  
USA

\*Corresponding author: fzjzhang@  
ucdavis.edu

## Abstract:

The CpoBD13 is a  $\beta$ -defensin found in saltwater crocodile. This compound has potential applications in antifungal drug development. As part of nature immune system in crocodile, this peptide represents strong antifungal activity against certain pathogen, it can disrupt certain fungal cell membranes specifically. Its unique mechanism, which binds with phospholipids in fungal membranes, destabilize the membranes, and cause cell death eventually, makes it differs from traditional antifungal treatment. This mechanism disrupts fungal physically and therefore largely reduced the resistance issue developed among fungal. With its pH-sensitive nature, CpoBD13 can easily adopted to acidic environments, this allows it to interact with fungal membranes more intensely, also allows it to be more active in infected areas, like injuries on skins. Although some challenges remain in its stability and viability, new therapies against fungal infections can be discovered through this animal-derived peptides. Further study and research are needed to refine the application and production of CpoBD13 in clinical treatment. To better fill this research gap, this paper aims to discover the mechanism, the potential application, and the future expectation of CpoBD13 in clinical use.

**Keywords:** CpoBD13, antifungal activity, animal-derived, membrane disruption

## 1. Introduction

The products derived from nature including plants, microorganisms, and animals have long been a potential source for medical use. The sulfur-containing natural products obtained from marine has become a reliable resolution for a series of clinical issue [1]. And a bacteria called Burkholderia can provide insights for new antibiotic agents [2]. Among these,

antimicrobial peptides are often tailored to disrupt microbial membranes and are relatively crucial due to their effectiveness against bacterial, viral, and fungal pathogens. It is different compared with traditional antibiotics, which are becoming useless gradually due to the enhancing resistance. As the resistance of diverse pathogens evolved, public health may cannot merely rely on antibiotics, and the antimicrobial peptides become a helpful alternative [3]. This structure

can be found in a wide range of life forms, including reptiles.

As a very ancient species, crocodile has existed for billions of years. The secret of their tenacious lives lies within their bodies. CpoBD13 is a pH-Sensitive  $\beta$ -Defensin from the Saltwater Crocodile with potent antifungal activity, it is one such peptide that shows potential in curing fungal infections. This immune system allows crocodiles to withstand various pathogens, including fungi.

Nevertheless, since humans are mammals while crocodiles are reptiles, there is a huge difference between the antimicrobial peptides of the two. It is not certain whether the peptides can function well without negative effects as medical treatment for human use. The following will discuss how CpoBD13 works to kill fungus, what and how CpoBD13 can be used as potential treatment, and what scientists can work on to eliminate this research gap.

## 2. CpoBD13 & Mechanism:

CpoBD13 is a  $\beta$ -defensin, which is one of the antimicrobial peptides found in the saltwater crocodile. Defensins are important parts of the innate immune system. CpoBD13 is unique in its structure which has a high proportion of histidine residues. This peptide contains around 13 percent of histidine content, where human peptides only have 3 to 5 percent, contributing to its ability to function in a pH-sensitive manner [4]. Its antifungal activity is regulated by surrounding environmental pH. At acidic environment, the peptide becomes more positively charged, enhancing its ability to bind to and penetrate fungal membranes.

The antifungal activity of CpoBD13 is primarily attributed to its ability to interact with and disrupt fungal cell membranes. CpoBD13 binds to the negatively charged phospholipid components of fungal membranes, forming pores that lead to the leakage of cellular contents and eventual cell death. This special ability is also well-seen in the defensin of plants [4]. Unlike traditional antifungal agents that target specific intracellular processes, CpoBD13's mechanism is based on a physical disruption of the membrane integrity, making it less likely to induce resistance. When pH is low, the peptide adopts a more positively charged conformation, which enhances its ability to bind to the fungal membrane. This pH-dependent activation ensures that CpoBD13 is more active in acidic environments, such as those found in infected tissues. Amazingly, CpoBD13 only has a little or no evident effect on human cell dynamic [4]. Furthermore, CpoBD13 is very connected to the phosphatidic acid in fungal membranes, which is unique compared to other defensins [4].

## 3. Potential Applications

With these mechanisms and its unique properties, it could serve multiple future applications.

**Antifungal Drug Development:** CpoBD13 has strong antifungal activity, especially against *Candida albicans*, a common pathogenic fungus [4]. Its ability to disrupt fungal cell membranes through binding to phosphatidic acid makes it a valuable tool in curing fungal infections. Its antifungal activity is especially vigorous in acidic environments, which is related for treating infections in human tissues that often have a lower pH. Scientists surveyed and synthesized current research on cationic host defense peptides, which can directly kill microbes, can modulate the host immune response by helping resolve inflammation and hence enhance host defenses. Strategies including optimized analogs and peptides derivation engineering are reviewed to design synthetic peptides that have high activity and with minimal toxicity to humans. Scientists emphasized the antimicrobial peptide-based treatments are very promising therapies against infections [5].

**Selective Targeting of Fungal Cells:** Unlike many traditional antifungal drugs that can also harm human cells, CpoBD13 does not exhibit toxicity towards mammalian cells at the concentrations effective against fungi. This specificity could result in a safer therapeutic treatment effect with fewer side effects. Scientists performed several cell viability assays, including MTT and live cell imaging, to assess the metabolic activity of live cells and have visual confirmation of cell viability [6]. Scientists also investigated the  $\beta$ -defensin of American alligator. They synthesized the peptide chemically and used it to against a range of bacteria, including both Gram-positive and Gram-negative strains. One peptide, Am23SK, demonstrated strong activity against both planktonic cells and biofilms, by the meantime it shows no cytotoxic effects to mammalian cells, which suggests these peptides can target fungal cells selectively [4] [7].

**Adapt in Acidic Infections:** PH plays a vital role in the biological process of wound healing, including immune response. The pH at wound could change locally based on different body's defense mechanism [8]. The pH-sensitive nature of CpoBD13 allows it to be activated in acidic environments, such as those found in infected tissues. This characteristic makes it particularly useful for treating localized infections, such as skin wounds where the pH may be altered by the infection. In another study, scientists also proved that pH could mediate peptide activity of humans. They Prepared standardized bacterial cultures, treated them with individual peptides across different pH buffers, measured bacterial viability, and compared effects across pH conditions. The results however show that in

acidic condition, the activity of human peptide, in airways particularly, is weakened [9]. This result highlights the advantage of CpoBD13, as it can compensate the shortage of human peptide.

**Broad Range of Antifungal Potential:** CpoBD13 has been shown to have activity against certain kinds of fungal pathogens. This activity could make it an important tool in treating various fungal infections if scientists make variants based on CpoBD13, particularly those resistant to current antifungal drugs. There is already a case that scientists derived a minimal template from naturally occurring defensins and synthesized this artificial peptide chemically to ensure its proper folding and structural integrity [10]. With the evolve of this technique, better artificially revised or improved peptide based on CpoBD13 can be developed to response to more variety of pathogen.

**Combination Therapies:** As mentioned in another research, combination strategies are recommended when dealing with serious *Candida* infections, as treating it with one single antifungal is not effective [11]. Given its unique mechanism of action, CpoBD13 could be used in combination with other antifungal medicines to enhance therapeutic efficacy and overcome resistance mechanisms. Its ability to target and disrupt fungal cell membranes could complement the functions of other drugs, providing a multi-functional resolution to infection issues.

**Potential for Access and Large-Scale Production:** CpoBD13 can be easily obtained from Saltwater Crocodile, allowing for large-scale production. This could make it accessible for clinical applications. As many livestock these days are genetically engineered to fulfill human needs, cows for examples, have been manipulated to produce fully human antibodies effective against diseases like Ebola [12]. Scientists may also cultivate and breed crocodiles using some of the eggs to gain large amount of peptide.

## 4. Discussion:

Despite CpoBD13 shows promising antifungal activity, the defensins of reptiles, including crocodiles, are poorly characterized compared to other defensins from plants and mammals. This limits the understanding of their full information and drug sensitivities. And while the pH-sensitive nature of CpoBD13 is beneficial, it also creates challenges related to its stability and effective use in different physiological conditions. Ensuring the stability of the peptide in environment with varying pH value, as well as its activity during storage and use might be difficult and need further research and study. Also, more studies related to its effectiveness of other fungal species and its safety towards human cells are required.

## 5. Conclusion:

CpoBD13, a  $\beta$ -defensin derived from the saltwater crocodile, could be a potential source for new medicine treated for fungal infection. It can treat fungal infections efficiently based on its unique pH-sensitivity and membrane-disrupting properties. Its harmlessness towards mammalian cells could reduce the side effects.

Besides its potential value, there are also several challenges in optimizing CpoBD13 for clinical use. These include ensuring the stability in varying pH environments and applying its effectiveness against a broader range of fungal pathogens. Additionally, more detailed studies on the peptide mechanism and its interactions with other pathogens are needed to fully understand its therapeutic potential.

## References

- [1] Guo, F.-W., Zhang, Q., Gu, Y.-C., & Shao, C.-L. (2023). Sulfur-containing marine natural products as leads for drug discovery and development. *Current Opinion in Chemical Biology*, 75, 102330–102330. <https://doi.org/10.1016/j.cbpa.2023.102330>
- [2] Depoorter, E., Bull, M. J., Peeters, C., Coenye, T., Vandamme, P., & Mahenthiralingam, E. (2016). *Burkholderia*: an update on taxonomy and biotechnological potential as antibiotic producers. *Applied Microbiology and Biotechnology*, 100(12), 5215–5229. <https://doi.org/10.1007/s00253-016-7520-x>
- [3] Ji, S., An, F., Zhang, T., Lou, M., Guo, J., Liu, K., Zhu, Y., Wu, J., & Wu, R. (2024). Antimicrobial peptides: An alternative to traditional antibiotics. *European Journal of Medicinal Chemistry*, 265, 116072–116072. <https://doi.org/10.1016/j.ejmech.2023.116072>
- [4] Williams, S. A., Lay, F. T., Bindra, G. K., Banjara, S., Poon, I. K. H., Phan, T. K., Kvensakul, M., & Hulett, M. D. (2023). Crocodile defensin (CpoBD13) antifungal activity via pH-dependent phospholipid targeting and membrane disruption. *Nature Communications*, 14(1), 1170. <https://doi.org/10.1038/s41467-023-36280-y>
- [5] Mookherjee, N., Anderson, M. A., Haagsman, H. P., & Davidson, D. J. (2020). Antimicrobial host defence peptides: functions and clinical potential. *Nature Reviews Drug Discovery*, 19(5), 311–332. <https://doi.org/10.1038/s41573-019-0058-8>
- [6] Phan, T. K., Lay, F. T., Poon, I. K. H., Hinds, M. G., Kvensakul, M., & Hulett, M. D. (2015). Human  $\beta$ -defensin 3 contains an oncolytic motif that binds PI(4,5)P<sub>2</sub> to mediate tumour cell permeabilisation. *Oncotarget*, 7(2), 2054–2069. <https://doi.org/10.18632/oncotarget.6520>
- [7] Santana, F. L., Arenas, I., Haney, E. F., Estrada, K., Hancock, R. E. W., & Corzo, G. (2021). Identification of a crocodylian  $\beta$ -defensin variant from *Alligator mississippiensis* with antimicrobial and antibiofilm activity. *Peptides*, 141, 170549.

<https://doi.org/10.1016/j.peptides.2021.170549>

[8] Percival, S. L., McCarty, S., Hunt, J. A., & Woods, E. J. (2014). The effects of pH on wound healing, biofilms, and antimicrobial efficacy. *Wound Repair and Regeneration*, 22(2), 174–186. <https://doi.org/10.1111/wrr.12125>

[9] Alaiwa, M. H. A., Reznikov, L. R., Gansemer, N. D., Sheets, K. A., Horswill, A. R., Stoltz, D. A., Zabner, J., & Welsh, M. J. (2014). pH modulates the activity and synergism of the airway surface liquid antimicrobials  $\beta$ -defensin-3 and LL-37. *Proceedings of the National Academy of Sciences*, 111(52), 18703–18708. <https://doi.org/10.1073/pnas.1422091112>

[10] Nikolinka Antcheva, Morgera, F., Creatti, L., Vaccari, L.,

Pag, U., Pacor, S., Shai, Y., Sahl, H.-G., & Alessandro Tossi. (2009). Artificial  $\beta$ -defensin based on a minimal defensin template. *Biochemical Journal*, 421(3), 435–447. <https://doi.org/10.1042/bj20082242>

[11] Baddley, J. W., & Pappas, P. G. (2005). Antifungal Combination Therapy. *Drugs*, 65(11), 1461–1480. <https://doi.org/10.2165/00003495-200565110-00002>

[12] Redwan, el-Rashdy M. (2009). Animal-derived pharmaceutical proteins. *Journal of Immunoassay & Immunochemistry*, 30(3), 262–290. <https://doi.org/10.1080/15321810903084400>